Cabaletta Bio Inc (CABA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.28-9.86%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · CABA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of 2026-11-04 · Compared with 66 industry peers
CABA — litigation filed
Dated 2026-06-03
Other Events. On June 3, 2026, the Company posted to the “Investors & Media” section of the Company’s website at www.cabalettabio.com an updated corporate presentation (the “Corporate Presentation”). A copy of the Corporate Presentation is attached hereto as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference. On June 3, 2026, the Company issued the Press Release announcing new rese-cel data and development updates across the Company's autoimmune portfolio, in…
Why it matters: Higher doses test if rese-cel can work without preconditioning. Clear responses would build on early results at the lowest dose.
Supportive ifNew data from patients treated with higher doses and no PC show clinical responses in both RESET-PV and RESET-SLE. Follow-up is also reported.
Worry ifHigher-dose data from either trial show no clinical responses. Or, the company reports a safety issue that stops dose testing.
Why it matters: This tests whether Cabaletta can use its no-preconditioning approach in another disease. A start would turn the plan into trial activity.
Supportive ifThe company reports that a patient has been dosed in a PC-free RESET-MG cohort.
Worry ifThe next company update says PC-free RESET-MG dosing has not started or has been dropped.
Why it matters: The company plans to fund operations into mid-2027. That window includes key trial work and the planned myositis data report.
Worry ifThe next financial update still says current cash can fund the operating plan into mid-2027 or later.
Less concerning ifThe company says cash will not fund the operating plan into mid-2027, or reports a shorter runway.
Why it matters: The 17-patient study is meant to support Cabaletta's first BLA filing. The response rate and safety results will test that plan.
Watch forMid-2027 results show responses at the 16-week main check, with no new serious safety concern.
Also watch forThe study misses its response goal, reports a serious safety concern, or the data report slips past mid-2027.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$350 on $10,000 · ±3.5% | How much price usually moves either way. |
| Bad day | $756 loss on $10,000 · 7.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,747 loss on $10,000 · 67.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.